Kidney RSS News Feeds

Nephrology

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Boers M et al. – The placebo phase of registration trials for RA can be limited to 3 months. An accompanying viewpoint proposes to then switch placebo patients to standard of care, allowing a more valid and comprehensive assessment including safety.

Methods

Results

Exclusive Author Commentary
Maarten Boers, 11/03/09

In the print edition hopefully appearing soon, I've outlined a new trial design that encorporates the above findings: patients in the placebo group are mandatorily switched to standard of care (usually anti-TNF) after 3 months. This allows secondary head-to-head comparisons. Please note that I'm NOT advocating that the total trial duration should be limitied to 3 months.

   

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Send this Summary to a Colleague

Enter email address